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Summary
Interleukin (IL)-17 plays a critical role in inflammation. Most studies to date
have elucidated the inflammatory role of IL-17A, often referred to as IL-17.
IL-17F is a member of the IL-17 family bearing 50% homology to IL-17A
and can also be present as heterodimer IL-17AF. This study elucidates the
distribution and contribution of IL-17A, F and AF in inflammatory arthritis.
Neutralizing antibody to IL-17A alone or IL-17F alone or in combination
was utilized in the mouse collagen-induced arthritis (CIA) model to eluci-
date the contribution of each subtype in mediating inflammation. IL-17A, F
and AF were all increased during inflammatory arthritis. Neutralization of
IL-17A reduced the severity of arthritis, neutralization of IL-17A+IL-17F had
the same effect as neutralizing IL-17A, while neutralization of IL-17F had no
effect. Moreover, significantly higher levels of IL-17A and IL-17F were
detected in peripheral blood mononuclear cells (PBMC) from patients with
rheumatoid arthritis (RA) in comparison to patients with osteoarthritis
(OA). IL-17A and AF were detected in synovial fluid mononuclear cells
(SFMC) in RA and OA, with IL-17A being significantly higher in RA
patients. Enriched CD3+ T cells from RA PBMCs produced singnificantly
high levels of IL-17A and IL-17AF in comparison to OA peripheral blood
CD3+ T cells. IL-17A, F and AF were undetectable in T cells from SFMCs
from RA and OA. While IL-17A, F, and AF were all induced during CIA,
IL-17A played a dominant role. Furthermore, production of IL-17A, and not
IL-17F or IL-17AF, was elevated in PBMCs, SFMCs and enriched peripheral
blood CD3+ T in RA.
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Introduction
Interleukin (IL)-17 plays an undisputed role in mediating
inflammation. The IL-17 family consists of six subtypes,
IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, with a
16–50% homology of B–F to IL-17A. IL-17F has about 50%
homology to IL-17A. IL-17A and F can be secreted as
homodimers as well as the heterodimer IL-17AF [1,2].
The pathogenic role of IL-17A in inflammatory arthritis
has been reported in studies involving neutralization
of IL-17A and in IL-17A-deficient mice [3,4]. The
pathogenic potential of other IL-17 subtypes has been
reported in studies where T cells transduced with IL-17A,
IL-17F, IL-17B or IL-17C all induced joint inflammation
in the mouse model of collagen-induced arthritis (CIA)
and neutralization of IL-17B reduced the severity of
CIA [5]. The vast majority of studies on rheumatoid
arthritis (RA) reporting increased levels of IL-17 are
focused on IL-17A, frequently referred to as IL-17 [6–10].
There is limited information regarding the expression of
other subtypes. IL-15-mediated induction of IL-17C, E
and F has been reported in mononuclear cells from RA
[11]. IL-17A, IL-17F and IL-17C were increased signifi-
cantly in psoriatic skin [12]. Moreover, IL-17A and, to a
lesser extent, IL-17F was shown to induce a similar set of
inflammatory genes in RA synovial fibroblasts [13,14].
These reports suggest that inflammatory potential is not
restricted to IL-17A alone, but also extends to other sub-
types of IL-17 in preclinical models as well as in human
diseases.
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The studies in this report are focused on elucidating the
contribution of IL-17A, F and AF responses in CIA and RA.
We have also performed head-to-head studies of in-vivo
neutralization of IL-17A, IL-17F, and IL-17A+IL-17F in CIA
to establish the contribution each of these cytokines in
mediating joint inflammation.
Materials and methods
Collagen-induced arthritis
Experiments involving animals were carried out in accord-
ance with institutional guidelines under protocol approved
by the Animal Care and Use Committee of the University of
Arizona. All efforts were made to minimize suffering. Eight
to 10-week-old male DBA1 mice were purchased from
Taconic Farms (Hudson, NY, USA). Arthritis was induced
following immunization with collagen and complete
Freund’s adjuvant (CFA). CFA was prepared by mixing
heat-inactivated mycobacterial strain H37Ra in incomplete
Freund’s adjuvant (4 mg/ml) and was mixed with
lympholized chicken collagen (Chondrex, Redmond, WA,
USA) dissolved overnight in acetic acid (4 mg/ml) at 1:1 to
form an emulsion which was injected intradermally at the
base of the tail. Clinical scoring of arthritis, assay of anti-
collagen antibodies and tissue histology of paws were
undertaken as described previously [15].
Generation of mouse IL-17F antibody mAb (I17M502)
Solution-based panning of the Centocor pIX de-novo Fab
libraries was performed based on previously used Centocor
de-novo library panning techniques [16]. Specifically, Fab
library phage libraries were mixed and separated by heavy
chain gene, then blocked for 1 h with 3% milk in 1 × phos-
phate-buffered saline Tween 20 (PBST). Microcentrifuge
tubes were blocked with 3% milk in 1 × PBST for 1 h; 50 μl
of Dynabeads (Dynal/Life Technologies, Paisley, Scotland,
UK) per library were washed with 1 × PBS and blocked with
3% milk in PBST for 1 h at room temperature (RT) rotat-
ing. Bt-mIL-17F at 100 nM was also blocked for 1 h at RT
rotating with 0·3% milk in PBST, then mixed with the
blocked library phage for 1 h. Blocked streptavidin beads
were incubated with the phage/antigen solution for 30 min.
Beads were captured magnetically and washed 10 times
with PBST. Cells were plated out evenly on 3–150 mm
Luria-Bertani LB broth with carbenicillin (LB/Carb)/1%
glucose plates (Teknova, Hollister, CA, USA) and incubated
overnight at 37°C. Cells were scraped from the agar plates
into 2 × yeast extract and tryptone (YT) media and 50 μl
was used to inoculate 20 ml of 2 × YT/carb and grown at
37°C shaking for 2 h. Cultures were then infected with 1 ml
of VCSM13 helper phage and incubated for 30 min at 37°C
without shaking before adding kanamycin (35 μg/ml) and
isopropyl β-D-1-thiogalactopyranoside (IPTG) (1 mM) and
incubating overnight at 30°C [17]. The panning process was
repeated for a total of three rounds. Following the third
round of panning, cells were harvested for plasmid DNA
miniprep. DNA was cut with NheI and SpeI enzymes to
remove the pIX gene and the vector DNA was gel isolated,
ligated and transformed to obtain single colonies for
screening. Single colonies were picked and expressed in
deep 96-well plates by induction with IPTG. Cultures were
centrifuged and supernatants were used for soluble Fab
screening against mouse IL-17F coated on a Maxisorp plate
(1 μg/ml) and for Fab expression by binding to sheep anti-
human FD (The Binding Site, Birmingham, UK) coated on
a Maxisorp plate. Fabs were detected in both enzyme-linked
immunosorbent assays (ELISAs) using anti-kappa horse-
radish peroxidase (HRP) (Southern Biotech, Birmingham,
AL, USA) and detection with electrochemical luminescence
substrate (Roche, Basel, Switzerland). Clones that demon-
strated inhibition of IL-17F binding to mouse IL-17RC
were subjected to affinity maturation. Polymerase chain
reaction (PCR)-amplified heavy chains were cloned into LC
libraries as described [16]. Panning was executed as
described above, but with lower concentrations of bt-mIL-
17F, 1 nM for all three rounds. Clones were screened as
detailed above. Unique clones were converted to immuno-
globulin (Ig)G and further characterized for affinity and
inhibition of IL-17F activity. Neutralization activity of
I17M502 was demonstrated in vitro via inhibition of
IL-17F-induced epithelial cell-derived chemokine produc-
tion from CMT93 cells (data not shown).
Administration of neutralizing antibodies
Mouse anti-IL-17A and isotype control antibodies were a
kind gift from Dr Merle Elloso (Janssen Research and
Development, L.L.C., Spring House, PA, USA). Mouse anti-
IL-17F was generated as above. For experiments involving
administration of neutralizing antibodies, each mouse
received 100 μg of specific antibody+100 μg of respective
isotype control antibody or 100 μg each of both isotype
control antibodies, daily via the intraperitoneal (i.p.) route.
Mouse tissue harvest and culture set-up
Splenocytes or draining inguinal lymph nodes were har-
vested from mice 2 weeks following immunization with col-
lagen (initiation phase) and from arthritic mice. Single-cell
suspensions (5 × 106/ml) of splenocytes were stimulated
with collagen (100 μg/ml; Chondrex, Redmond, WA, USA),
in the presence or absence of IL-23 (100 ng/ml; Peprotech,
Rocky Hill, NJ, USA) for 6 days. Culture supernatants were
collected and frozen in −80°C for further analyses.
Human subjects
The study was approved by the Human Research Ethics
Committee of the University of Arizona and the partici-
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pant’s written consent was obtained in accordance with the
terms of the ethics committee of the University of Arizona.
Forty patients who fulfilled the 1987 American College of
Rheumatology (ACR) criteria for RA and 19 patients with
osteoarthritis (OA) were recruited for this study. Blood
samples were collected from all subjects, although in some
cases the yield was insufficient for all assays. Synovial fluid
mononuclear cells (SFMCs) were collected from eight
patients with RA and nine patients with OA at the Univer-
sity of Michigan, under a protocol approved by the Human
Research Ethics Committee of the University of Michigan.
Collection of peripheral blood and processing
Peripheral blood was collected by venipuncture into
heparinized tubes or DNA tubes. Peripheral blood
mononuclear cells (PBMCs) were isolated from heparinized
blood using Ficoll-Paque density gradient (GE Healthcare,
Little Chalfont, UK). PBMCs or synovial fluid mononuclear
cells (SFMCs) were cultured at 5 × 106 cells/ml with
phorbol myristate acetate (PMA) (5 ng/ml)/ionomycin
(500 ng/ml) for 6 h or 24 h and culture supernatants were
collected and stored at −80°C until further analyses. DNA
was prepared from blood, and shared epitope alleles were
analysed at the University of Arizona Genetics Core
genotyping core, University of Arizona, using the human
leucocyte antigen (HLA)-DRB1 genotyping kit from Qiagen
(Venlo, the Netherlands).
CD3+ T cell isolation from PBMCs and SFMCs
CD3+ T cells were enriched from PBMCs or SFMCs from
some RA and OA patients using a human T cell enrichment
kit (Miltenyi Biotech, San Diego, CA, USA), according to
manufacturer’s protocol. Purified CD3+ T cells were then
cultured at 5 × 106 cells/ml with PMA (5 ng/ml)/ ionomycin
(500 ng/ml) for 24 h and culture supernatants were col-
lected and stored at −80°C until further analyses.
Flow cytometry
For intracellular flow cytometry, cells were stimulated
briefly with PMA/ionomycin and brefeldin A, followed by
surface staining of CD4 (anti-CD4 cloneGK1·5; Biolegend,
San Diego, CA, USA) and intracellular staining with anti-
IL-17A (clone TC11-18H10·1; Biolegend) and anti-IL-17F
(clone eBio18F10; eBioscience, San Diego, CA, USA).
Fluorescently labelled isotype-matched antibodies were
used as controls. Flow cytometry data was acquired with BD
LSR and analysed with FlowJo software (TreeStar, Inc.,
Ashland, OR, USA).
Cytokine analysis
Mouse and human IL-17A, IL-17F and IL-17AF in culture
supernatants were analysed utilizing kits from eBioscience.
We validated the manufacturer’s data and found no cross-
reactivity between ELISA for IL-17A, IL-17F and IL-17AF
(data not shown). IL-6, IFN-γ, IL–1β, TNF-α, granulocyte
colony-stimulating factor (G-CSF) and granulocyte–
macrophage colony-stimulating factor (GM-CSF) were
measured in mouse sera by Luminex assay using kits from
R&D Systems (Minneapolis, MN, USA).
Statistical analysis
All ELISA and real-time PCR assays were performed in trip-
licate. Differences among groups were analysed by Student’s
t-test or Mann–Whitney U-test. Correlation was analysed
by Pearson’s correlation analysis. P-value of <0·05 was con-
sidered significant.
Results
IL-17A, F and AF are induced during CIA
IL-17A, IL-17F and IL-17AF were analysed in draining
inguinal lymph nodes or splenocytes in naive mice, mice
from the initiation phase of CIA (2 weeks following immu-
nization with collagen and CFA) and from arthritic mice.
Data in Fig. 1a show that IL-17A and F were not present in
naive mice. IL-17A is induced first, during the initiation
phase, with 0·488% CD4 cells being positive for IL-17A,
which increases to 1·20% of total CD4 cells with the onset
of arthritis. IL-17F is only induced upon the onset of arthri-
tis with 1·23% of CD4 cells being positive for IL-17F. Inter-
estingly, only a very small percentage of CD4 cells stained
positive for both IL-17A and IL-17F. Similar results were
obtained with draining inguinal lymph nodes (data not
shown).
It is well accepted that IL-17A is induced during CIA as a
consequence of anti-CII responses [15,18]. Figure 1b shows
that during the initiation phase both IL-17A and IL-17AF
were induced in a collagen-specific manner. In keeping with
the undetectable levels of IL-17F by flow cytometry during
the initiation phase (Fig. 1a), IL-17F was not detectable in
culture supernatants. IL-23 induced a significant increase in
IL-17A only. There was no increase in IL-17AF levels in the
cultures when IL-23 was added. Figure 1c shows that
IL-17A, IL-17F and AF were detectable in cultures of
splenocytes from arthritic mice stimulated with collagen,
with IL-17F levels lower than IL-17A or IL-17AF. IL-23
selectively induced IL-17A without any significant change in
IL-17F or IL-17AF.
To summarize, IL-17A and IL-17F were induced during
arthritis and were produced by discrete cell populations.
Furthermore, IL-17AF is also produced during CIA.
IL-17A plays a dominant pathogenic role in CIA
So far our studies showed that IL-17A, IL-17AF and, to a
lesser extent, IL-17F were induced during CIA. In order to
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elucidate the pathogenic potential of IL-17A, F and AF
during CIA, mice were immunized with collagen and CFA
followed by administration of neutralizing antibodies or
matched isotype controls daily starting from day 20. The
experimental groups included (i) anti-IL-17A+isotype
control for anti-IL-17F; (ii) anti-IL-17F+isotype control for
anti-IL-17A; (iii) anti-IL-17A+anti-IL-17F; and (iv) isotype
control for anti-IL-17A+isotype control for anti-IL-17F.
Data in Fig. 2a show that mice receiving anti-IL-17A or
anti-IL-17A+anti-IL-17F antibodies had significantly
reduced clinical severity of arthritis compared to mice that
received anti-IL-17F alone or isotype control antibodies.
Figure 2b depicts representative micrographs from each
group. Figure 2c shows that joint inflammation, synovitis,
cartilage damage and bone erosion scores were all reduced
significantly in mice that received anti-IL-17A alone or anti-
IL-17A+anti-IL-17F in comparison to mice that received
anti-IL-17F alone or isotype control antibody.
Anti–IL-17A antibody treatment suppresses serum
IgG2b and proinflammatory cytokines IL-6 and G-CSF
Anti-collagen antibodies play a critical pathogenic role in
CIA, hence it is plausible that the differential effects of
IL-17A and IL-17F on clinical arthritis were associated with
differences in anti-collagen antibody responses. IgG1, IgG2a
and IgG2b anti-collagen antibody responses were measured
in sera from mice receiving various interventions. Data in
Fig. 3a show that there were no differences in IgG1 anti-
collagen antibody responses between the groups. Adminis-
tration of anti-IL-17A alone or anti-IL-17F alone did not
alter IgG2a responses, whereas a combination of
IL-17A+IL-17F reduced IgG2a anti-collagen antibodies. In
contrast, administration of anti-IL-17A alone, anti-IL-17F
alone or anti-IL-17A+anti-IL-17F significantly reduced
IgG2b responses. These findings show that both IL-17A and
IL-17F have similar effects on anti-collagen antibody
responses; however, neutralization of IL-17A significantly
reduced arthritis severity.
In addition to intact anti-collagen antibody responses,
joint inflammation in CIA is dependent upon robust
cytokine responses, including IL-6, IL-1β, IFN–γ, TNFα,
G-CSF and GM-CSF. Of these cytokines, IL-17A has been
reported to directly induce the secretion of G-CSF, IL-6,
IL-1β, GM-CSF and TNF-α [18–20]. In order to elucidate if
the differential effect of anti-IL-17A and anti-IL-17F on
arthritis was due to differences in the regulation of the
above cytokines in vivo, IL-6, IFN-γ, IL-1β, TNF-α, G-CSF
and GM-CSF were measured in sera from mice receiving
anti-IL-17A, anti-IL-17F, anti-IL-17A+anti-IL-17F or
isotype control antibodies. IL-6 and G-CSF were suppressed
significantly in mice treated with anti-IL-17A or anti-IL-
17A+anti-IL-17F antibody in comparison to mice receiving
isotype control antibody (Fig. 3b). As noted above, mice
receiving anti-IL-17A or anti-IL-17A+anti-IL-17F antibody
had significantly reduced severity of arthritis. There was no
suppression of IL-6 or G-CSF in mice receiving anti-IL-17F
antibody and mice in this group did not have any reduction
in their arthritis severity. Surprisingly, IL-6 levels were
increased in mice receiving anti-IL-17F antibody in com-
parison to mice receiving isotype control. IFN-γ, IL-1β,
TNF-α and GM-CSF were not altered among the various
groups of mice (Fig. 3b).
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Fig. 1. Interleukin (IL)-17A, F and AF
responses are induced in collagen-induced
arthritis (CIA). (a) Splenocytes from naive
mice, mice from initiation phase (2 weeks
following immunization with collagen and
complete Freund’s adjuvant (CFA) and arthritic
mice were stimulated for 6 h with phorbol
myristate acetate (PMA)/ionomycin and
brefeldin A and stained for anti-CD4, IL-17A
and IL-17F. Data shown are gated on CD4. Data
are representative of three separate experiments.
(b,c) Splenocytes of mice from initiation phase
and arthritic mice were stimulated with collagen
in the presence or absence of IL-23 for 7 days,
followed by analyses of IL-17A, F and AF
responses in culture supernatants by
enzyme-linked immunosorbent assay (ELISA).
Data are representative of two separate
experiments. **P < 0·005.
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While we did not find suppression of IL-1β, TNF-α,
IFN-γ or GM-CSF in any group of mice, the data depicting
the suppression of IL-6 and G-CSF by anti-IL-17A are in
line with previous reports supporting the augmentation of
IL-6 and G-CSF by IL-17A during inflammation [3,21–23].
Although previous studies have reported the induction of
TNF-α and IL-1β by IL-17A in human macrophages, we
did not find any change in systemic levels of TNF-α or
IL-1β upon administration of anti-IL-17A during CIA [21].
Furthermore, the unaltered levels of TNF-α do not rule out
the pathogenic role of TNF-α, either alone or in synergy
with IL-17A. Our data, showing the unaltered levels of
IFN-γ with the administration of anti-IL-17A, are in line
with a previous study elucidating unchanged levels of T
helper type 1 (Th1) responses following administration of
anti-IL-17A antibody during inflammatory arthritis [24].
Studies elucidating the effector function of IL-17A or
IL-17F on RA synovial cells have reported that while IL-17A
and IL-17F may induce similar sets of genes, IL-17A was
potent in inducing most inflammatory genes, including
IL-6 and G-CSF, in comparison to IL-17F [13,25]. Thus, our
data on IL-6 and G-CSF are in keeping with previous data,
supporting the possibility of a more dominant role of
IL-17A over IL-17F during arthritis. These findings suggest
that the protective effect of anti-IL-17A or anti-IL-
17A+anti-IL-17F on arthritis may be due to the selective
suppression of IL-6 and G-CSF.
Collectively, our data demonstrate that IL-17A plays a
dominant role over IL-17F in the regulation of inflamma-
tory arthritis. Additionally, while IL-17A and IL-17F may
have similar effects on the regulation of B cell production of
anti-collagen antibodies, IL-17A has a dominant effect on
IL-6 and G-CSF in-vivo.
IL-17A, F, and AF in peripheral blood mononuclear
cells of patients with RA
In order to corroborate our data pertaining to IL-17A, F
and AF obtained in the preclinical model of CIA with the
human disease RA, IL-17A, F and AF were analysed in
PBMCs of patients with RA. Clinical and demographic
characteristics of the patients with RA are outlined in
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Fig. 2. Interleukin (IL)-17A plays a dominant pathogenic role in collagen-induced arthritis (CIA). Thirty-two DBA1 mice were immunized to
induce arthritis. Mice were divided into four groups of eight mice each (1) anti-IL-17A+isotype of anti-IL-17F; (2) anti-IL-17F+isotype of
anti-IL-17A; (3) anti-IL-17A+anti-IL-17F; (4) isotype of IL-17A+isotype of IL-17F. All mice received 100 μg of antibodies daily starting at day 21
post-immunization with collagen and complete Freund’s adjuvant (CFA) (shown as arrow). (a) Data shown as cumulative arthritis score per group.
*P = 0·01. (b) Data show the histology of haematoxylin and eosin staining of representative paws from the four groups of mice, magnification ×10.
(c) Data show the histological scoring of paws from various groups. *P < 0·05; ** P < 0·005; ***P < 0·0005.
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Table 1. PBMCs from patients with RA or OA were stimu-
lated with PMA/ionomycin for 6 or 24 h followed by analy-
sis of IL-17A, IL-17F and IL-17AF by ELISA. Upon
stimulation of PBMCs with PMA/ionomycin, IL-17A, F and
AF were not detectable at 6 h (data not shown). Figure 4
shows the levels of IL-17A, F and AF in PBMCs of patients
with RA or OA stimulated for 24 h. Levels of IL-17A and F
in culture supernatants of PBMCs from RA were higher
than in OA, whereas the levels of IL-17AF were similar in
the two groups. In our preliminary studies, only very small
numbers of cells were positive for IL-17A or IL-17F by
intracellular flow cytometry and hence this technique was
not utilized for further assays involving human samples. In
our studies the serum levels of IL-17A, F and AF were too
low (below 5 pg/ml) to be able to detect reliably without
interference of heterophilic antibodies [26]. Hence, serum
levels of IL-17A, F and AF were not utilized for this study.
Clinically, RA is a heterogeneous disease with variable
levels of serological markers and a range of clinical severity.
More than 50% of patients with RA are positive for anti-
cyclic citrullinated peptides (CCP) antibody and patients
positive for this antibody also have increased severity of
arthritis, suggesting that perhaps the IL-17 responses of
patients positive for anti-CCP antibody might be distinct
from patients negative for this antibody. In our studies,
however, the levels of IL-17A, F or AF following stimulation
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Fig. 3. Anti-interleukin (IL)-17A antibody
treatment suppresses serum immunoglobulin
(Ig)G2b and proinflammatory cytokines IL-6
and granulocyte colony-stimulating factor
(G-CSF). (a) Experimental design was the same
as for Fig. 2 above. Serum drawn at the time of
harvest was analysed for anti-collagen antibody
using enzyme-linked immunosorbent assay
(ELISA), as outlined in Materials and methods.
**P < 0·005; ***P < 0·0005; n.s. = not
significant. Data are from five to eight mice in
each group. (b) Serum from various groups of
mice was analysed for cytokine IL-6, interferon
(IFN)-γ, IL–1β, G-CSF, GM-CSF and tumour
necrosis factor (TNF)-α by Luminex assay.
*P < 0·05; **P < 0·005; ***P < 0·0005; n.s. = not
significant. Data are from five to eight mice in
each group.
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with PMA/ionomycin were similar among patients with RA
who were anti-CCP-positive versus anti-CCP-negative (data
not shown). While the aetiology of RA remains to be unrav-
elled, it is thought that a combination of genetic risk alleles
and environmental triggers plays a key role in this disease.
To date, HLA-DRB1 alleles that contain the shared epitope
(SE) have been shown to have the strongest association with
RA [27,28]. The SE is contained in the HLA-DRB1 alleles
*0401, *0404, *0405, *0408, *0413, *0101, *0102, *1402 and
*1001 [27,29]. We wanted to evaluate whether patients car-
rying one or two alleles of the SE had higher levels of
IL-17A, F or AF following stimulation with PMA/
ionomycin in comparison to patients who did not have any
copies of the SE alleles. Our studies showed no differences
in the levels of IL-17A, F or AF among patients carrying one
or two copies of the shared epitope (data not shown). Fur-
thermore, we did not find any significant correlations
between levels of IL-17A, F and AF with duration of disease,
clinical severity as assessed by disease activity score 28
(DAS28) score, 44 tender and swollen joint count, erythro-
cyte sedimentation rate (ESR) or C-reactive protein (CRP)
(data not shown).
In summary, IL-17A and IL-17F were higher in patients
with RA in comparison to patients with OA, irrespective of
serological status, presence or absence of shared epitope or
disease activity.
IL-17A, F and AF responses in SFMCs
It is very well-recognized that systemic responses may not
be the same as joint-specific responses. In order to elucidate
joint-specific IL-17A, F and AF responses, we stimulated
SFMCs from patients with RA or OA with PMA/ionomycin
for 6 or 24 h. IL-17A, F or AF were not detectable in SFMCs
cultured with PMA/ionomycin for 6 h (data not shown).
Our data in Fig. 5 show that IL-17A and AF were detectable
in supernatants of SFMCs in RA and OA cultured for 24 h.
RA SFMC cultures produced more IL-17A than OA cul-
tures, but equal amounts of IL-17AF. IL-17F was not detect-
able in cultures of RA or OA SFMCs (data not shown).
These findings suggest that IL-17A and IL-17AF are pre-
dominantly present in target tissues in comparison to
IL-17F. The very small numbers of IL-17A- or IL-17F-
producing cells in our preliminary assays precluded us from
utilizing intracellular flow cytometry to study IL-17A and
IL-17F responses in a reliable manner in joint SFMCs.
IL-17A, F and AF responses in purified CD3+ T cells
from PBMCs or SFMCs
It has been reported earlier that IL-17A is expressed mainly
by T cells, and hence we wanted to elucidate IL-17A, F and
AF responses from purified CD3+ T cells from PBMCs or
SFMCs. CD3+ T cells from PBMCs or SFMCs of patients
Table 1. Demographic and clinical features of subjects with rheuma-
toid arthritis (RA) [pertaining to Fig. 4: RA peripheral blood
mononuclear cells (PBMC)].
RA cohort (n = 40)
n (%)
Female subjects [n (%)] 32 (80)
Anti-CCP + [n (%)] (in n = 38 patients)† 23 (60)
SE 1 copy (in n = 32 patients)‡ 16 (50)
SE 2 copies (in n = 32 patients)‡ 3 (9·3)
On prednisone 10 (25)
On DMARDS (methotrexate, azathioprine,
leflunomide)
35 (87·5)
On NSAIDS and narcotic pain medications 5 (12·5)
On anti-TNF therapy 3 (7·5)
Mean (s.d.)
DAS28 4·0 (1·6)
Tender swollen joint count 44 12·33 (10·85)
ESR 24·3 (23·8)
CRP (in n = 36 patients)§ 10·28 (13·51)
†Data on anti-cyclic citrullinated peptide (CCP) status was not avail-
able in two patients. ‡Data on shared epitope not available for eight
patients. §Data on level of C-reactive protein (CRP) not available for
four patients. ESR = erythrocyte sedimentation rate; DAS28 = disease
activity score 28; TNF = tumour necrosis factor; NSAID = non-
steroidal anti-inflammatory drugs; DMARD = disease-modifying anti-
rheumatic drugs; SE = shared epitope; s.d. = standard deviation.
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Fig. 4. Interleukin (IL)-17A, F and AF in peripheral blood mononuclear cells of patients with rheumatoid arthritis (RA). Peripheral blood
monuclear cells (PBMCs) from patients with RA or osteoarthritis (OA) were stimulated with phorbol myristate acetate (PMA)/ionomycin for 24 h
and IL-17A, IL-17F and IL-17AF were analysed in culture supernatant by enzyme-linked immunosorbent assay (ELISA). *P < 0·05; n.s. = not
significant.
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with RA or OA were cultured with PMA/ionomycin for
24 h. Our data in Fig. 6 show that IL-17A and AF were
detectable in supernatants of CD3+ T cells from PBMCs
from patients with RA cultured with PMA/ionomycin for
24 h and were significantly higher than T cells from patients
with OA. IL-17F was not detectable (data not shown). Addi-
tionally, IL-17A, F and AF were not detectable in superna-
tants of CD3+ T cells isolated from SFMCs from patients
with RA (n = 5) or OA (n = 5) (data not shown). These
findings suggest that peripheral blood T cells from patients
with RA produce increased amounts of IL-17A and
IL-17AF. Furthermore, SFMC T cells are probably not the
major producer of IL-17A, F or AF.
Discussion
IL-17A and IL-17F can form homodimers or a heterodimer
IL-17AF [1]. In this report we show that IL-17A, F and AF
were all induced during CIA. IL-17A is induced first, follow-
ing immunization with collagen, and increases upon onset
of arthritis, while IL-17F is induced upon arthritis onset.
Moreover, IL-17A and IL-17F are produced by discrete sets
of CD4 T cells, and there is differential regulation of
IL-17A, IL-17F and IL-17AF, with IL-23 preferentially
inducing IL-17A over IL-17F and IL-17AF. These findings
are in keeping with recent reports supporting the differen-
tial regulation of IL-17A and IL-17F in primary cell cul-
tures, lymphoma and lupus [30–34].
Even though IL-17A, F and AF were increased during
CIA, administration of anti-IL-17A reduced the severity of
arthritis, suggesting a dominant role of IL-17A over IL-17F.
Furthermore, while heterodimer IL-17AF was detectable
during CIA, neutralization with anti-IL-17A was sufficient
to reduce arthritis, further supporting the dominant role of
IL-17A. Our findings confirm previous studies reporting
the amelioration of CIA upon administration of anti-IL-
17A polyclonal antibody and reduced severity of CIA in
IL-17A-deficient mice, and provide direct evidence that
IL-17F plays a lesser role. Blocking of IL-17A may be suffi-
cient to reduce the effects of the heterodimer IL-17AF [3,4].
IL-17A and IL-17F both bind to the same receptor
complex comprised of IL-17RA and IL-17RC, and induce
expression of similar inflammatory cytokines and
chemokines [13,14,25,35] In keeping with this similarity,
anti-IL-17A or anti-IL-17F had similar effects on anti-
collagen antibody responses and neutralization of both
(anti-IL-17A+anti-IL-17F) had a more profound effect than
neutralization of either IL-17A or IL-17F. Interestingly,
while neutralization of IL-17A was associated with reduced
anti-collagen IgG2b responses and a reduced severity of
arthritis, the reduced pathogenic anti-collagen IgG2b
response seen with neutralization of IL-17F was not associ-
ated with a reduction in the severity of arthritis. This result
suggests that other pathways, including IL-17A, may be
critical for mediating arthritis, specifically in the absence of
IL-17F.
The cytokines IL-6, IL-1β, TNFα, IFN-γ, G-CSF and
GM-CSF have all been reported to be associated with
inflammatory arthritis. While IL-17A and IL-17F may
potentially induce similar sets of inflammatory genes,
IL-17A is a more potent inducer of most inflammatory
cytokines, including IL-6, IL-1β, G-CSF and GM-CSF, than
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Fig. 5. Interleukin (IL)-17A, F and AF
responses in synovial fluid mononuclear cells
(SFMCs). Mononuclear cells from synovial fluid
of patients with rheumatoid arthritis (RA)or
osteoarthritis (OA) were stimulated with
phorbol myristate acetate (PMA)/ionomycin for
24 h and analysed for IL-17A, F and AF by
enzyme-linked immunosorbent assay (ELISA).
**P < 0·005; n.s. = not significant.
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Fig. 6. Interleukin (IL)-17A, F and AF responses in purified CD3+ T cells from peripheral blood monuclear cells (PBMCs) or synovial fluid
mononuclear cells (SFMCs). Purified CD3(+) T cells from patients with rheumatoid arthritis (RA) (n = 9) or osteoarthritis (OA) (n = 6) were
stimulated with phorbol myristate acetate (PMA)/ionomycin for 24 h and IL-17A, IL-17F and IL-17AF were analysed in culture supernatant by
enzyme-linked immunosorbent assay (ELISA). **P < 0·005; ***P < 0·0005.
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is IL-17F [13,18–20,25]. In our study we found that mice
which received anti-IL-17A or anti-IL-17A+anti-IL-17F had
significantly reduced arthritis, along with significant and
robust reduction of the levels of serum IL-6 and G-CSF.
Administration of anti-IL-17F was not associated with
reduced levels of IL-6 or G-CSF or reduced severity of
arthritis. These findings are in keeping with previous
studies in RA synovial fibroblasts reporting a differential
effect of IL-17A and IL-17F [13,25]. It is possible that the
leading role of anti-IL-17A over IL-17F may be mediated
via its preferential effects on IL-6 and/or G-CSF in vivo.
IL-17A and IL-17F levels were higher in cultured PBMCs
from RA in comparison to OA. There were no differences in
the levels of IL-17AF produced by PBMCs from RA and OA.
IL-17A, F and AF responses in RA were similar in subjects
with RA who were anti-CCP+ versus subjects who were anti-
CCP–, or among patients positive or negative for the SE allele.
Furthermore, there was no correlation with duration or
severity of RA, suggesting that the activation of the IL-17
pathway is not restricted to certain patients within the RA
population but is elevated with inflammation in a large
number of patients with RA. Stimulation of SFMCs of sub-
jects with RA and OA showed increased levels of IL-17A in
RA. There were no significant differences in the levels of
IL-17AF. IL-17F was undetectable in these cultures. In
keeping with the increased levels of IL-17A in PBMCs from
patients with RA in comparison to patients with OA, IL-17A
was also significantly higher in peripheral blood CD3+ T cells
in patients with RA. Interestingly, while IL-17F levels were
elevated in RA PBMCs versus OA PBMCs, peripheral blood
CD3+ T cells did not produce IL-17F, suggesting that in RA,
IL-17F is probably produced by non-T cells in the peripheral
blood. Peripheral blood CD3+ T cells from patients with RA
produced significantly increased levels of IL-17AF in com-
parison to peripheral blood CD3+ T cells of patients with OA.
This is in contrast to similar levels of IL-17AF from PBMCs
among patients with RA or OA. This is due probably to
varying percentages of T cells in peripheral blood in the
donor population. IL-17A was elevated significantly in
SFMCs from patients with RA; however, neither IL-17A, F
nor AF were detectable in CD3+ T cells from SFMCs of
patients with RA or OA. This is in keeping with a previous
study reporting that mast cells and not Th17 cells are the
major source of IL-17A in the RA joint [36]. It is possible that
the IL-17 subtypes (A, F and AF) are produced by discrete
cells and regulated differentially in peripheral blood and
joints of patients with RA and OA.
Other subtypes of IL-17, including B, C, D and E, may
also mediate inflammation. It has been reported that IL-17B
and IL-17C can induce joint inflammation in CIA [5]. Fur-
thermore, IL-17C, E and F are induced by IL-15 in joint
mononuclear cells from patients with RA, and IL-17C has
been shown to be increased in psoriatic skin [11,12].
Further studies are needed to elucidate comprehensively the
role of each subtype in inflammation.
Overall, our data in an animal preclinical model establish
that while IL-17A, IL-17F and IL-17AF are all present in
inflammatory arthritis, IL-17A plays a dominant role over
IL-17F. Moreover, blockade of IL-17A was sufficient to neu-
tralize the effect of IL-17AF. Furthermore, production of
IL-17A, and not IL-17F or IL-17AF, was elevated in PBMCs
and SFMCs in RA. Our studies support the concept that
IL-17A is the major contributor to IL-17-related inflamma-
tory effects in RA. Clinical trials with anti-IL-17A antibod-
ies are ongoing (Secukinumab NCT 01640938 and
Ixekizumab NCT 00966875), the results of which will shed
additional light on the importance of IL-17A in mediating
inflammation in RA.
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